Medicare has launched a new pilot program offering GLP-1 weight-loss drugs for $50 monthly co-pays starting July 1, according to multiple reports. The initiative, called Medicare GLP-1 Bridge, provides access to medications like Novo Nordisk's Wegovy and Eli Lilly's Zepbound and Foundayo for eligible beneficiaries aged 65+ or with disabilities.
Key Takeaways
Medicare launched a pilot program offering GLP-1 weight-loss drugs for $50 monthly co-pays starting July 1. Eligible beneficiaries include those aged 65+ or with disabilities who meet specific BMI criteria.
- Medicare's new pilot offers Wegovy, Zepbound, and Foundayo to eligible seniors
- Patients pay a $50 monthly copay under the temporary program set to end in December 2027
- Eligibility requires meeting specific BMI thresholds or having certain health conditions
⚖
▼Source Claims Check
2 Differences FoundAll 3 publishers report consistent facts across 3 key claims. 2 points of difference noted.
| Claim | Status | Reason | |
|---|---|---|---|
| Program Duration | 1 Difference | CBS News and Fox News report that the program runs from July 1, 2026 to December 31, 2027. Reuters says it is through the end of 2027. | ▼ |
| Eligibility Requirements | 1 Difference | CBS News and Fox News report that eligibility requires a BMI of at least 35, or a BMI of at least 30 plus certain health conditions. Reuters says it includes a BMI of 25-29.9 or over 30 with certain health conditions. | ▼ |
| Program Start Date | Broad Agreement | July 1, 2024 | |
| Covered Medications | Broad Agreement | Wegovy, Zepbound KwikPen injection and Foundayo pill | |
| Program Cost | Broad Agreement | $50 monthly copay for patients, $250 per month covered by Medicare. |
Program Duration
▼CBS News and Fox News report that the program runs from July 1, 2026 to December 31, 2027. Reuters says it is through the end of 2027.
Eligibility Requirements
▼CBS News and Fox News report that eligibility requires a BMI of at least 35, or a BMI of at least 30 plus certain health conditions. Reuters says it includes a BMI of 25-29.9 or over 30 with certain health conditions.
Program Start Date
Broad AgreementJuly 1, 2024
Covered Medications
Broad AgreementWegovy, Zepbound KwikPen injection and Foundayo pill
Program Cost
Broad Agreement$50 monthly copay for patients, $250 per month covered by Medicare.
This analysis is AI-generated and may not perfectly represent each source's reporting. Always read the original articles for full context.
The program marks the first time Medicare will cover drugs prescribed solely for obesity rather than other conditions. Eligible patients must meet specific BMI criteria: a BMI of at least 30 plus certain health conditions, or a BMI between 27-29.9. Those already covered for GLP-1s through Medicare Part D are not eligible.
The pilot will run until the end of 2027, with uncertain long-term prospects. According to CBS News, KFF estimates that about 3.8 million Medicare beneficiaries could qualify under these requirements. However, experts warn about potential challenges in managing older adults' weight loss safely and effectively.
Clinicians have expressed concerns about the program's sustainability and implementation. As reported by Reuters, Dr. John Batsis from UNC Chapel Hill noted that access to clinical support may not keep pace with drug availability. Additionally, rapid weight loss in older adults could lead to muscle mass loss and reduced bone mineral density.
Medicare Administrator Dr. Mehmet Oz told reporters that CMS plans to track participation and outcomes carefully. The program's future beyond 2027 remains uncertain, as it will depend on data collected during the pilot phase and potential congressional action.
How this summary was created
This summary synthesizes reporting from 3 independent publishers using AI. All sources are cited and linked below. NewsBalance is a news aggregator and media literacy tool, not a news publisher. AI-generated content may contain errors or inaccuracies — always verify important information with the original sources.